1. Home
  2. CLMB vs DMAC Comparison

CLMB vs DMAC Comparison

Compare CLMB & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CLMB

Climb Global Solutions Inc.

HOLD

Current Price

$20.74

Market Cap

387.6M

Sector

Technology

ML Signal

HOLD

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

HOLD

Current Price

$5.81

Market Cap

347.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLMB
DMAC
Founded
1982
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
387.6M
347.5M
IPO Year
1996
2018

Fundamental Metrics

Financial Performance
Metric
CLMB
DMAC
Price
$20.74
$5.81
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$80.00
$15.50
AVG Volume (30 Days)
186.8K
139.1K
Earning Date
04-29-2026
05-13-2026
Dividend Yield
0.60%
N/A
EPS Growth
14.29
N/A
EPS
0.18
N/A
Revenue
$652,517,000.00
$500,000.00
Revenue This Year
$7.82
N/A
Revenue Next Year
$5.83
N/A
P/E Ratio
$113.67
N/A
Revenue Growth
40.14
N/A
52 Week Low
$15.25
$3.48
52 Week High
$145.00
$10.42

Technical Indicators

Market Signals
Indicator
CLMB
DMAC
Relative Strength Index (RSI) 36.37 39.96
Support Level $18.97 $5.76
Resistance Level $23.60 $6.40
Average True Range (ATR) 1.07 0.37
MACD 1.24 -0.04
Stochastic Oscillator 92.10 26.48

Price Performance

Historical Comparison
CLMB
DMAC

About CLMB Climb Global Solutions Inc.

Climb Global Solutions Inc is a cloud-based, value-added IT distribution and solutions company specializing in emerging technologies. It operates across the USA, Canada, United Kingdom, and Europe through multiple business units, including Climb Channel Solutions, Sigma, Grey Matter, Interwork, and TechXtend. The company is organized into two reportable operating segments. The Distribution segment distributes technical software to corporate resellers, value-added resellers (VARs), consultants, and systems integrators under the name Climb Channel Solutions. The Solutions segment is a cloud solutions provider and value-added reseller of software, hardware, and services to customers under the name Grey Matter.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: